List of Psychotropic Drugs 30032010

Total Page：16

File Type：pdf, Size：1020Kb

Lista psykotrooppisista lääkkeistä List of Psychotropic drugs ตารางแสดงการแบงประเภทวัตถุออกฤทธิ์ตอจิตและประสาท Psykotrooppiset lääkkeet Psykotrooppiset ryhmä 1 lääkkeet ryhmä 2 Psykotrooppiset lääkkeet ryhmä 3 Psykotrooppiset lääkkeet ryhmä 4 Psychotropic drugs Psychotropic drugs schedule 1 schedule 2 Psychotropic drugs schedule 3 Psychotropic drugs schedule 4 วัตถุออก ฤทธิ์ในประเภท 1 วัตถุออก ฤทธิ์ในประเภท 2 วัตถุออก ฤทธิ์ในประเภท 3 วัตถุออก ฤทธิ์ในประเภท 4 Cathinone Amfepramone Pemoline Amobarbital Allobarbital Fludiazepam DET Amineptine Phenylpropanolamine Buprenorphine Alprazolam Halazepam DMHP Aminorex Phencyclidine Butalbital Barbital Inorganic Bromide DMT Butorphanol Phendimetrazine Cyclobarbital Benzphetamine (paitsi Lithium Bromide, jota Etryptamine Brotizolam Phenmetrazine Glutethimide Bromazepam käytetään kylmäkoneteollisuudessa sekä GHB (Gamma-hydroxybutyrate) Cathine Phentermine Meprobamate Butobarbital Potassium Bromide Technical Methcathinone Ephedrine Pipradrol Pentazocine Camazepam Grade ja Sodium Bromide Mescaline Estazolam Pseudoephedrine Pentobarbital Chloral hydrate and its adducts Technical Grade, jota käytetään Mescaline derivatives Fencamfamin Quazepam Chlordiazepoxide Ketazolam valokuvien teettämisessä) Mescaline analog Fenethylline Secobarbital Chlorphentermine Escaline Flunitrazepam Temazepam Clobazam Lorazepam Isoproscaline Flurazepam Triazolam Clonazepam Medazepam Proscaline Haloxazolam Zaleplon Clorazepate tai Clorazepic acid Mefenorex 4-Thiomescaline tai 4-TM Ketamine Zipeprol Nordazepam Methyprylon 4-Thioescaline tai 4-TE Loprazolam Zolpidem Oxazepam Methylphenobarbital 4-Thioproscaline tai 4-TP Lormetazepam Zopiclone Oxazolam Perlapine 3-Thiomescaline tai 3-TM Mazindol Clortermine Phenobarbital 3-Thioescaline tai 3-TE Methylphenidate Clotiazepam Pinazepam 3-Thiometaescaline tai 3-TME Mesocarb Cloxazolam Prazepam 4-methylaminorex Midazolam Diazepam Propylhexedrine Parahexyl N-Ethylamphetamine Delorazepam Pyrovalerone PCE Nimetazepam Ethchlorvynol Secbutabarbital PHP(PCPY) Nitrazepam Ethinamate SPA Psilocine Ethyl loflazepate Tetrazepam Psilocybine Fenproporex Tofisopam TCP Vinylbital Tetrahydrocannabinol Huomioi: Listan lääkeaineiden nimikkeet ovat englanniksi Tuonti ja vienti Thaimaahan kielletty Maahantuontiin tarvitaan lääkärintodistus englanninkielellä sekä lääkkeiden määrä ei saa ylittää 30 päivän annosta. Katso toimintaohjeet edellisen sivun tiedotteesta "Ohjeet matkustajalle, jolla on matkatavarana psykotrooppisiin tai huumausaineisiin luokiteltavia lääkeaineita" kohta 1B..

Copy Link

Recommended publications

Direct Preparation of Some Organolithium Compounds from Lithium and RX Compounds Katashi Oita Iowa State College
Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1955 Direct preparation of some organolithium compounds from lithium and RX compounds Katashi Oita Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Organic Chemistry Commons Recommended Citation Oita, Katashi, "Direct preparation of some organolithium compounds from lithium and RX compounds " (1955). Retrospective Theses and Dissertations. 14262. https://lib.dr.iastate.edu/rtd/14262 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overiaps.
[Show full text]
What's the Best First Line Anticonvulsant?
What’s the best first line anticonvulsant? Stephen Hanson, DVM, MS, Dip. ACVIM (Neurology) Recurring seizure activity is a relatively common problem in canine patients. Nowadays, there are several good options for medical treatment, which makes the choice of which drug to use a little more complicated. All anticonvulsant drugs have advantages and disadvantages, so the selection of a first-line drug should be tailored for the individual patient and client. Phenobarbital: This has been the standard first choice drug for decades. The nice thing about Phenobarbital is that it works fairly well, controlling seizures in about 70% of dogs with epilepsy. Also, it is inexpensive and readily available. The biggest down-sides are its induction of hepatic metabolism and the need for frequent upward dose adjustments, as well as its potential to cause hepatotoxicity. The potential for liver disease increases with time, so a 2 year old dog placed on this medication is more likely to develop hepatotoxicity in his life-time than a 10 year old dog. Phenobarbital can also cause sedation and ataxia. While this is usually mild/transient, it can be a real problem in dogs with other pre- existing signs of intracranial disease. Polyuria, polydipsia and polyphagia are other common side effects. These signs vary widely in severity between patients. Pros: cheap, available at any corner pharmacy, works well Cons: higher doses required with time, possible serious liver side-effects Good first-line choice for middle-aged to older dogs without any pre-existing liver issues Poor choice for dogs with liver disease, dogs with other intracranial signs Questionable choice for young epileptic dogs Potassium/sodium bromide: This was the most commonly-used add on anticonvulsant drug for a long time.
[Show full text]
Drug & Alcohol Testing Program
Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
[Show full text]
Uso Adecuado De BZD En Insomnio Y Ansiedad.Pdf
Vol. 6 Nº 1 · OCTUBRE 2014 BOLETÍN CANARIO DE USO RACIONAL DEL MEDICAMENTO DEL SCS Uso adecuado de BENZODIAZEPINAS en insomnio y ansiedad. SUMARIO PERFIL FARMACOLÓGICO DE LAS BZD (Tabla 1). - INTRODUCCIÓN 1 - PERFIL FARMACOLÓGICO DE LAS BENZODIAZEPINAS 1 No todas las BZD son iguales, ni tienen las mismas indicaciones. - BENZODIAZEPINAS EN EL INSOMNIO 2 Conocer algunos aspectos sobre su perfil farmacológico es esencial para realizar una prescripción adecuada y segura. - BENZODIAZEPINAS EN LA ANSIEDAD 4 - RECOMENDACIONES PARA SUSPENDER 5 Por lo general las BZD se absorben muy bien por vía oral, mientras TRATAMIENTOS CON BZD que la vía intramuscular presenta una absorción lenta e irregular, por - BIBLIOGRAFÍA 7 lo que no suele ser muy recomendada. En situaciones de emergencia (convulsiones) es preferible utilizar la vía endovenosa. INTRODUCCIÓN Inicio de acción y vida media: el inicio de acción es distinto según el principio activo y constituye un criterio fundamental en la selección de Las benzodiazepinas (BZD) son psicofármacos que actúan aumentan- las BZD. Puede ser: de inicio rápido (0,5-1 h), de utilidad en el insomnio do la acción del ácido gammaaminobutírico (GABA), principal neuro- de conciliación y en crisis de ansiedad; de inicio intermedio (1-3 h) o transmisor inhibidor del sistema nervioso central. Tienen indicaciones de inicio lento (> 3 h), preferibles en insomnio de mantenimiento o terapéuticas diversas, y auque su uso más habitual es en el tratamien- despertar precoz y en la ansiedad generalizada. to de la ansiedad e insomnio, también se utilizan en la inducción a la anestesia, en el tratamiento de las crisis comiciales, en el síndrome La vida media de las BZD es otro de los criterios de selección y puede 5 de abstinencia alcohólica, como tratamiento coadyuvante de de dolor ser : corta (< 6 h); intermedia (6-24 h) y larga (> 24 h).
[Show full text]
Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa been reported with administration of triazolam. tient’s mental status revealed that he was extreme Rebound insomnia6 and early morning insom ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal.
[Show full text]
Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
[Show full text]
Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
[Show full text]
Withdrawing Benzodiazepines in Primary Care
PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
[Show full text]
Syntheses and Eliminations of Cyclopentyl Derivatives David John Rausch Iowa State University
Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1966 Syntheses and eliminations of cyclopentyl derivatives David John Rausch Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Organic Chemistry Commons Recommended Citation Rausch, David John, "Syntheses and eliminations of cyclopentyl derivatives " (1966). Retrospective Theses and Dissertations. 2875. https://lib.dr.iastate.edu/rtd/2875 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. This dissertation has been microfilmed exactly as received 66—6996 RAUSCH, David John, 1940- SYNTHESES AND ELIMINATIONS OF CYCLOPENTYL DERIVATIVES. Iowa State University of Science and Technology Ph.D., 1966 Chemistry, organic University Microfilms, Inc., Ann Arbor, Michigan SYNTHESES AND ELIMINATIONS OF CYCLOPENTYL DERIVATIVES by David John Rausch A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OF PHILOSOPHY Major Subject: Organic Chemistry Approved : Signature was redacted for privacy. Signature was redacted for privacy. Head of Major Department Signature was redacted for privacy. Iowa State University Of Science and Technology Ames, Iowa 1966 ii TABLE OF CONTENTS VITA INTRODUCTION HISTORICAL Conformation of Cyclopentanes Elimination Reactions RESULTS AND DISCUSSION Synthetic Elimination Reactions EXPERIMENTAL Preparation and Purification of Materials Procedures and Data for Beta Elimination Reactions SUMMARY LITERATURE CITED ACKNOWLEDGEMENTS iii VITA The author was born in Aurora, Illinois, on October 24, 1940, to Mr.
[Show full text]
Chemical Resistance: Deco-Trowel
CHEMICAL RESISTANCE DECO-TROWEL ® SERIES 223 Tnemec Company, Inc. 6800 Corporate Drive Kansas City, Missouri 64120-1372 +1 816-483-3400 www.tnemec.com © December 16, 2019 by Tnemec Company, Inc. Chem223 Page 1 of 19 CHEMICAL RESISTANCE DECO-TROWEL ® | SERIES 223 COMMON PROBLEM AREAS FOR COATINGS AND SOLUTIONS Problem: Coating Solution: Points of failure Carefully and due to thin spots fully coat in coating Problem: Rough Pinhole Solution: Uneven Undercut Grind smooth welds Problem: Gaps between Solution: plates, coating Continuous can not cover welds Problem: Gaps between Solution: plates, coating Continuous can not cover welds Problem: Coating Sharp surface Solution: contours create Round the thin spots in contours coating Problem: Skip welding Solution: creates gaps Continuous that coating welds can not cover Problem: Skip welding Solution: creates gaps Continuous that coating welds can not cover 2 channels back to back IMPORTANT: Definitions for the terms and acronyms used in this guide to describe the recommended exposures, along with other important information, can be found on the cover page of this guide or by contacting Tnemec Technical Service. Coatings should not be applied in a chemical exposure environment until the user has thoroughly read and understood the product information and full project details have been discussed with Tnemec Technical Service. Tnemec Company, Inc. 6800 Corporate Drive Kansas City, Missouri 64120-1372 +1 816-483-3400 www.tnemec.com © December 16, 2019 by Tnemec Company, Inc. Chem223 Page 2 of 19 CHEMICAL RESISTANCE DECO-TROWEL ® | SERIES 223 ¹ Product is NOT suitable for direct or indirect food contact. Intended Use and temperature information relates to product’s performance capabilities only.
[Show full text]
Benzodiazepine Group ELISA Kit
Benzodiazepine Group ELISA Kit Benzodiazepine Background Since their introduction in the 1960s, benzodiazepines have been widely prescribed for the treatment of anxiety, insomnia, muscle spasms, alcohol withdrawal, and seizure-prevention as they are depressants of the central nervous system. Despite the fact that they are highly effective for their intended use, benzodiazepines are prescribed with caution as they can be highly addictive. In fact, researchers at NIDA (National Institute on Drug Abuse) have shown that addiction for benzodiazepines is similar to that of opioids, cannabinoids, and GHB. Common street names of benzodiazepines include “Benzos” and “Downers”. The five most encountered benzodiazepines on the illicit market are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), diazepam (Valium), and temazepam (Restori). The method of abuse is typically oral or snorted in crushed form. The DEA notes a particularly high rate of abuse among heroin and cocaine abusers. Designer benzodiazepines are currently offered in online shops selling “research chemicals”, providing drug abusers an alternative to prescription-only benzodiazepines. Data defining pharmacokinetic parameters, drug metabolisms, and detectability in biological fluids is limited. This lack of information presents a challenge to forensic laboratories. Changes in national narcotics laws in many countries led to the control of (phenazepam and etizolam), which were marketed by pharmaceutical companies in some countries. With the control of phenazepam and etizolam, clandestine laboratories have begun researching and manufacturing alternative benzodiazepines as legal substitutes. Delorazepam, diclazepam, pyrazolam, and flubromazepam have emerged as compounds in this class of drugs. References Drug Enforcement Administration, Office of Diversion Control. “Benzodiazepines.” http://www.deadiversion.usdoj.gov/drugs_concern/benzo_1.
[Show full text]
Download Product Insert (PDF)
Product Information Escaline (hydrochloride) Item No. 14107 CAS Registry No.: 3166-82-3 Formal Name: 4-ethoxy-3,5-dimethoxy- O NH2 benzeneethanamine, monohydrochloride Synonym: 4-ethoxy Mescaline MF: • HCl C12H19NO3 • HCl O FW: 261.7 Purity: ≥98% O Stability: ≥2 years at -20°C Supplied as: A crystalline solid Laboratory Procedures For long term storage, we suggest that escaline (hydrochloride) be stored as supplied at -20°C. It should be stable for at least two years. Escaline (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the escaline (hydrochloride) in the solvent of choice. Escaline (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of escaline (hydrochloride) in these solvents is approximately 10, 3, 0.5 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of escaline (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of escaline (hydrochloride) in PBS, pH 7.2, is approximately 3 mg/ml. We do not recommend storing the aqueous solution for more than one day. Escaline is the phenethylamine analog of 3C-E and the 4-ethoxy analog of mescaline. Its agonist activity at the serotonin 1 5-HT2A receptor is 5-8 times greater than mescaline.
[Show full text]